N,N,N′,N′-Tetrakis(2-pyridylmethyl)ethylenediamine inhibits ligand binding to certain G protein-coupled receptors

European Journal of Pharmacology

Volumn 474, Issue 1, 2003, Pages 1-5

  Webster, Jack M ^a   Bentley, Matthew T ^a   Wojcikiewicz, Richard J H ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

G protein coupled receptor; Ligand binding; TPEN

Indexed keywords

CHELATING AGENT; CHOLECYSTOKININ RECEPTOR; DIPRENORPHINE; G PROTEIN COUPLED RECEPTOR; INOSITOL 1,4,5 TRISPHOSPHATE; IODINE 125; METHYLSCOPOLAMINE; MUSCARINIC AGENT; N,N,N',N' TETRAKIS(2 PYRIDYLMETHYL)ETHYLENEDIAMINE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; HUMAN CELL; LIGAND BINDING; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

EID: 0141825690     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)02005-3     Document Type: Article

References (24)

1. +3) and zinc in the hippocampus. Brain Res. 892:2001;51-62.
2. 2+ homeostasis in Ehrlich and Yoshida carcinomas. J. Biol. Chem. 260:1985;2719-2727.
3. Bays N.W., Gardner R.G., Seelig L.P., Joazeiro C.A., Hampton R. Hrd1p/Der3p is a membrane-anchored ubiquitin ligase required for ER-associated degradation. Nat. Cell Biol. 3:2001;24-29.
4. Campbell D.J., Rowbotham D.J., Lambert D.G. Do nitrous oxide and halothane influence opioid receptor binding in SH-SY5Y human neuroblastoma cells. Br. J. Anaesth. 75:1995;752-755.
5. Carter J.E., Truong-Tran A.Q., Grosser D., Ho L., Zalewski P.D. Involvement of redox events in caspase activation in zinc-depleted airway epithelial cells. Biochem. Biophys. Res. Commun. 297:2002;1062-1070.
6. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
7. Cherny R.A., Legg J.T., McLean C.A., Fairlie D.P., Huang X., Atwood C.S., Beyreuther K., Tanzi R.E., Masters C.L., Bush A.I. Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion. J. Biol. Chem. 274:1999;23223-23228.
8. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., Kim Y.-S., Huang X., Goldstein L.E., Moir R.D., Lim J.T., Beyreuther K., Zheng H., Tanzi R.E., Masters C.L., Bush A.I. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 30:2001;665-676.
9. Chimienti F., Seve M., Richard S., Mathieu J., Favier A. Role of cellular zinc in programmed cell death: temporal relationship between zinc depletion, activation of caspases, and cleavage of Sp family transcription factors. Biochem. Pharmacol. 62:2001;51-62.
10. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 21:2000;90-113.
11. Holtmann M.H., Hadac E.M., Miller L.J. Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. J. Biol. Chem. 270:1995;14394-14398.
12. 2+ and inositol 1,4,5-trisphosphate mass in a human neuroblastoma cell line, SH-SY5Y. Biochem. J. 265:1990;555-562.
13. Lambert D.G., Ghataorre A.S., Nahorski S.R. Muscarinic receptor binding characteristics of a human neuroblastoma SK-N-SH and its clones SH-SY5Y and SH-EP1. Eur. J. Pharmacol. 165:1989;71-77.
14. Law P.Y., Wong Y.H., Loh H.H. Mutational analysis of the structure and function of opioid receptors. Biopolymers. 51:1999;440-455.
15. Lorick K.L., Jensen J.P., Fang S., Ong A.M., Hatakeyama S., Weissman A.M. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc. Natl. Acad. Sci. U. S. A. 96:1999;11364-11369.
16. Oberdorf J., Webster J.M., Zhu C.C., Luo S.G., Wojcikiewicz R.J.H. Down-regulation of types I, II and III inositol 1,4,5-trisphosphate receptors is mediated by the ubiquitin/proteasome pathway. Biochem. J. 339:1999;453-461.
17. Silvente-Poirot S., Escrieut C., Wank S.A. Role of the extracellular domains of the cholecystokinin receptor in agonist binding. Mol. Pharmacol. 54:1998;364-371.
18. 2+ signaling through secretagogue and growth factor receptors on pancreatic AR4-2J cells. Regul. Pept. 55:1995;197-206.
19. Smith R.M., Martell A.E. Critical Stability Constants: Vol. 2. Amines. 1975;Plenum, New York.
20. Solano R.M., Langer I., Perret J., Vertongen P., Juarranz M.G., Robberecht P., Waelbroeck M. Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction. J. Biol. Chem. 276:2001;1084-1088.
21. Wess J. Mutational analysis of muscarinic acetylcholine receptors: structural basis of ligand/receptor/G protein interactions. Life Sci. 53:1994;1447-1463.
22. Wojcikiewicz R.J.H. Type I, II and III inositol 1,4,5-trisphosphate receptors are unequally susceptible to down-regulation and are expressed in markedly different proportions in different cell types. J. Biol. Chem. 270:1995;11678-11683.
23. 2+ and by rapid desensitization. J. Neurochem. 63:1994;177-184.
24. Wojcikiewicz R.J.H., Xu Q., Webster J.M., Alzayady K., Gao C. Ubiquitination and proteasomal degradation of endogenous and exogenous inositol 1,4,5-trisphosphate receptors in αT3-1 anterior pituitary cells. J. Biol. Chem. 278:2003;940-947.